Key result
IGF-I cuts postoperative renal dysfunction ~33% vs. placebo in high-risk vascular surgery.
Why the study?
Deterioration of renal function leading to postoperative renal failure is a complication of surgery involving the suprarenal aorta and renal arteries, and prevention strategies are needed.
Does insulin-like growth factor I prevent postoperative renal dysfunction in high-risk patients undergoing suprarenal aorta or renal artery surgery?
RCT (n=54)
Double-blind
randomized
Does insulin-like growth factor I prevent postoperative renal dysfunction in high-risk patients undergoing suprarenal aorta or renal artery surgery?
Postoperative administration of IGF-I is feasible and may reduce the incidence of renal dysfunction in high-risk patients undergoing major vascular surgery.
Answers are grounded in this paper and cite their sources.
May support postoperative IGF-I to lower renal dysfunction risk after high-risk aortic surgery; extends renoprotection evidence to vascular procedures.
Deterioration of renal function, which can lead to postoperative renal failure, is a complication of surgery involving the suprarenal aorta and surgery involving the renal arteries. Fifty-four patients who were at risk for developing this complication were enrolled in a double-blind, randomized, placebo-controlled trial of insulin-like growth factor (IGF-I) as a therapeutic agent to prevent the decline in renal function. The primary end point was the incidence of renal dysfunction, defined as a reduction of the glomerular filtration rate (creatinine clearance) at each of three measurements over 72 h. IGF-I (100 microg/kg subcutaneously every 12 h for 6 doses) or placebo was administered on admission to the intensive care unit immediately postoperatively. IGF-I- and placebo-treated groups were well matched for sex, age, type of surgery, renal ischemic time during surgery (ischemic index), baseline creatinine clearance, and baseline serum creatinine. No patient in the study developed acute renal failure postoperatively. IGF-I was well tolerated. A smaller proportion of patients in the IGF-I group had a postoperative decline in renal function (22%) than in the placebo-treated group (33%). There were no significant differences in levels of serum creatinine at time of discharge, length of hospital stay, length of intensive care unit stay, length of intubation, or incidence of dialysis or death. Our findings establish the feasibility and potential utility for the use of IGF-I to reduce the incidence of postoperative renal dysfunction in high-risk patients.
No takes yet. Share an insight, caveat, or question.
Franklin et al. (1997) conducted an RCT in Postoperative renal dysfunction (n=54). Insulin-like growth factor I (IGF-I) vs. Placebo was evaluated on Incidence of renal dysfunction, defined as a reduction of the glomerular filtration rate (creatinine clearance) at each of three measurements over 72 h. Insulin-like growth factor I reduced the incidence of postoperative decline in renal function compared to placebo in patients undergoing high-risk aortic or renal surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: